Treatment of obsessive-compulsive disorder with fluvoxamine: a multicentre, double-blind, placebo-controlled trial.

abstract：:The aim of this study was to investigate the prevalence of benzodiazepine and related drug (BZDR) use, especially long-term use, and associated factors among community-dwelling individuals with and without Alzheimer's disease (AD). We utilized data from the MEDALZ-2005 cohort, which includes all community-dwelling ind...

journal_title：International clinical psychopharmacology

authors： Taipale H,Koponen M,Tanskanen A,Tolppanen AM,Tiihonen J,Hartikainen S

更新日期：2015-07-01 00:00:00

abstract：:In an earlier study, we found a similar frequency of individuals with an abnormal correlation between serum leptin levels and body mass index (BMI) (outliers above or below the 95% confidence interval in the regression line) during treatment with antipsychotic drugs (n=301), other psychotropic drugs (n=65), and drug-f...

journal_title：International clinical psychopharmacology

authors： Marquina D,Peña R,Fernández E,Baptista T

更新日期：2011-05-01 00:00:00

abstract：:A number of compounds having an effect on serotonergic transmission have been shown to have a beneficial therapeutic action in patients with bulimia nervosa. Many previous studies, however, have suffered from methodological shortcomings, in particular small population sizes. This article reviews present data which sug...

journal_title：International clinical psychopharmacology

authors： Wood A

更新日期：1993-01-01 00:00:00

abstract：:A variety of cognitive impairments can be observed in patients with schizophrenia, including substantial reductions in the intelligence quotient (IQ). I propose that these impairments can be best understood in terms of the abnormal processes underlying the signs and symptoms manifested by the patient at the time of th...

journal_title：International clinical psychopharmacology

authors： Frith CD

更新日期：1995-09-01 00:00:00

abstract：:The pattern of brain metabolic changes produced by olanzapine has yet to be described, despite the theoretical and clinical interest of this new antipsychotic. We studied a group of 17 schizophrenic patients who underwent two fluoro-deoxyglucose-positron emission tomography (FDG-PET) studies under two different condit...

journal_title：International clinical psychopharmacology

authors： Molina V,Gispert JD,Reig S,Pascau J,Martínez R,Sanz J,Palomo T,Desco M

更新日期：2005-01-01 00:00:00

abstract：:The negative symptoms of schizophrenia remain a major clinical challenge. Reboxetine is an antidepressant whose major mechanism of action is as a noradrenergic reuptake inhibitor. This study was a 6-week randomized placebo-controlled trial of reboxetine or placebo add on to haloperidol 5 mg in the treatment of 30 pati...

journal_title：International clinical psychopharmacology

authors： Schutz G,Berk M

更新日期：2001-09-01 00:00:00

abstract：:The clock-drawing test (CDT) is used widely to evaluate cognitive disorders, but its role in the assessment of psychotic disorders has not been studied. We sought to examine whether the CDT plays a role as an indicator of psychosis and to establish its sensitivity to clinical improvement of psychosis. The CDT was admi...

journal_title：International clinical psychopharmacology

authors： Tene O,Sigler M,Shiloh R,Weizman A,Aizenberg D

更新日期：2016-05-01 00:00:00

abstract：:DEPRESS (Depression Research in European Society) is the first large pan-European survey of depression in the community. A total of 13359 of the 78463 adults who participated in screening interviews across six countries were identified as suffering from depression, a 6-month prevalence of 17%. Major depression account...

journal_title：International clinical psychopharmacology

authors： Lépine JP,Gastpar M,Mendlewicz J,Tylee A

更新日期：1997-01-01 00:00:00

abstract：:The 6-month prevalence of depression in the Italian community was evaluated by means of the modified-Mini-International-Neuropsychiatric Interview (MINI) administered with a computer-prompted interview to a representative panel of 3550 individuals. Major depression and minor depression accounted for 8.0% and 2.9% of t...

journal_title：International clinical psychopharmacology

authors： Dubini A,Mannheimer R,Pancheri P

更新日期：2001-01-01 00:00:00

abstract：:Out of ten consecutive patients with DSM-III-R obsessive-compulsive disorder without any previous history of bipolarity, three patients showed antidepressant-induced hypomania (clomipramine, one patient; fluvoxamine, two patients) within the first 5 to 8 weeks of the drug treatment. These data support the previous res...

journal_title：International clinical psychopharmacology

authors： Rihmer Z,Barsi J,Belsõ N,Pestality P,György S

更新日期：1996-09-01 00:00:00

abstract：:This analysis characterizes patients with schizophrenia or schizoaffective disorder treated with risperidone who met remission criteria. In a 50-week, open-label trial, stable patients received long-acting injectable risperidone every 2 weeks. Remission criteria included severity (absent-mild ratings on core symptoms ...

journal_title：International clinical psychopharmacology

authors： Docherty JP,Bossie CA,Lachaux B,Bouhours P,Zhu Y,Lasser R,Gharabawi GM

更新日期：2007-01-01 00:00:00

abstract：:Good evidence now exists for a therapeutic action of carbamazepine (CBZ) both in acute mania and in the prophylaxis of manic depression. Comparison with other existing therapies and incidence of adverse effects in psychiatric patients also deserve more clinical research. This paper reviews these clinical issues and th...

journal_title：International clinical psychopharmacology

authors： Elphick M

更新日期：1988-07-01 00:00:00

abstract：:Although the effects of atypical antipsychotics with regard to improving neurocognitive function are not sufficiently high. The present study applied an atypical antipsychotic monotherapy for patients with acute schizophrenia to (1) examine the percentage of patients who respond well to this treatment, (2) explore the...

journal_title：International clinical psychopharmacology

authors： Hori H,Yoshimura R,Katsuki A,Atake K

更新日期：2020-03-01 00:00:00

abstract：:We report a case of myoclonus induced by quetiapine. A 64-year-old man with schizophrenia developed myoclonic jerks when given higher doses of quetiapine. These movements were dose-related and completely abated on reducing the dose. To our knowledge, these movements have not been reported previously as an adverse effe...

journal_title：International clinical psychopharmacology

authors： Velayudhan L,Kirchner V

更新日期：2005-03-01 00:00:00

abstract：:We report that perospirone may have had positive effects on the obesity of three patients with schizophrenia and on the fasting blood sugar (FBS) and HbA1C of two of them who had type 2 diabetes mellitus. ...

journal_title：International clinical psychopharmacology

authors： Nishida M,Nakamura M

更新日期：2004-01-01 00:00:00

abstract：:The SSRIs differ from each other with regard to their chemical structure, their pharmacokinetics and their potential for causing pharmacokinetic interactions through inhibition of species of the cytochrome P450 enzyme system. Cytochrome P450 (CYP) is a group of more than 30 different heme containing proteins in humans...

journal_title：International clinical psychopharmacology

authors： Brøsen K

更新日期：1998-09-01 00:00:00

abstract：:An assessment of the efficacy of treatments in panic disorder and agoraphobia (PDA) is complicated by methodological problems resulting from the complexity of these disorders. In this paper, commonly used anxiety scales are discussed with regard to their relevance in the assessment of PDA. Although there are already m...

journal_title：International clinical psychopharmacology

authors： Bandelow B,Hajak G,Holzrichter S,Kunert HJ,Rüther E

更新日期：1995-06-01 00:00:00

abstract：:One of the most effective treatments for children with Attention Deficit Disorder with Hyperactivity (ADDH) has been the prescription of methylphenidate (MPH). While laboratory-based evidence indicates that MPH effects may be rate-dependent, little is known about changes evinced in operant behavior controlled by compl...

journal_title：International clinical psychopharmacology

authors： DuPaul GJ,Rapport MD,Vyse SA

更新日期：1988-10-01 00:00:00

abstract：:This double-blind study was performed on 10 aged insomniac patients who received, during 15 days, either triazolam (0.25 mg) or zopiclone (7.5 mg) at bed time. This in-patient period was bounded by two ambulatory periods of 5 days each, and two in-patient periods of 3 days each, during which the patients received a pl...

journal_title：International clinical psychopharmacology

authors： Mouret J,Ruel D,Maillard F,Bianchi M

更新日期：1990-04-01 00:00:00

abstract：:Platelet serotonin type 2A receptor (5-HT2A) sensitivity changes have previously been documented in depression, although it is unclear if this represents a stable trait marker of the illness, or whether it represents an acute state marker of depression that would change with treatment. Electroconvulsive therapy (ECT) ...

journal_title：International clinical psychopharmacology

authors： Plein H,Berk M

更新日期：2000-03-01 00:00:00

abstract：:Eighteen patients with rapid cycling bipolar affective disorder were recruited for an open trial of carbamazepine. Of these patients all but 2 had been resistant to lithium prophylaxis. Twelve of the patients were able to complete at least 6 months on carbamazepine. Of these 12 patients, 2 had a complete remission of ...

journal_title：International clinical psychopharmacology

authors： Joyce PR

更新日期：1988-04-01 00:00:00

abstract：:Fluvoxamine, a selective serotonin reuptake inhibitor, was investigated in a 6-week double-blind study among severely ill inpatients with DSM-III major depression. All but 1 patient also fulfilled criteria for melancholia. Following a 3-day placebo wash-out patients were randomly assigned to fluvoxamine, imipramine or...

journal_title：International clinical psychopharmacology

authors： Feighner JP,Boyer WF,Meredith CH,Hendrickson GG

更新日期：1989-07-01 00:00:00

abstract：:In a double-blind, between-patient clinical trial carbamazepine (CBZ) (n = 8) was compared to haloperidol (HP) (n = 9) in patients presenting with mania (DSM III). Seven patients on HP and 2 on CBZ failed to complete 4 weeks treatment. In 4 of the HP group this was because of extrapyramidal side-effects (EPS). Two pat...

journal_title：International clinical psychopharmacology

authors： Brown D,Silverstone T,Cookson J

更新日期：1989-07-01 00:00:00

abstract：:In this paper we review the history of antidepressant (AD) development, since the discovery of imipramine in 1957 to the present day. Through this exploration we will show that the increasing placebo response is likely a red herring and that a higher magnitude of placebo response is not an adequate explanation for AD ...

journal_title：International clinical psychopharmacology

authors： Khan A,Mar KF,Brown WA

更新日期：2018-09-01 00:00:00

abstract：:The prevalence of tardive dyskinesia in a consecutive series of 69 patients with bipolar affective disorder admitted to a catchment area service was found to be 19%. Prevalence increased with age and was related to the age of onset of bipolar disorder and number of previous episodes. Patients with tardive dyskinesia w...

journal_title：International clinical psychopharmacology

authors： Hunt N,Silverstone T

更新日期：1991-04-01 00:00:00

abstract：:Mood stabilizers are used clinically for the management of bipolar disorder. Prophylactic therapy with mood stabilizers is the primary treatment for preventing depressive and manic relapses in bipolar patients once they are stabilized. In this study, we examined the relative efficacy of the three most commonly used mo...

journal_title：International clinical psychopharmacology

authors： Peselow ED,Clevenger S,IsHak WW

更新日期：2016-07-01 00:00:00

abstract：:Using spectral analysis of heart rate, several studies have shown that panic disorder patients are characterized by a reduced heart rate variability (HRV), indicative of abnormalities in autonomous nervous system (ANS) function. We recently reported that patients with panic disorder, who did not respond to pharmacothe...

journal_title：International clinical psychopharmacology

authors： Slaap BR,Boshuisen ML,van Roon AM,den Boer JA

更新日期：2002-03-01 00:00:00

abstract：:A new selective MAO-A-inhibitor (noclobemide) was used in a double-blind comparative study of 23 patients with severe unipolar or bipolar depressive disorder. Two different doses of medication were given for 4 weeks. Effectiveness was measured by improvements in the Hamilton Rating Scale for Depression, a self-rating ...

journal_title：International clinical psychopharmacology

authors： Lensch K,Fuchs G,Böning J,Milech U

更新日期：1987-04-01 00:00:00

abstract：:Recently proposed criteria for remission by a 'Remission in Schizophrenia Working Group' have generated considerable interest. We assessed rates, predictors, and correlates of remission in a sample of patients with first-episode schizophrenia treated with injectable, long-acting risperidone. This allowed us to examine...

journal_title：International clinical psychopharmacology

authors： Emsley R,Oosthuizen P,Koen L,Niehaus DJ,Medori R,Rabinowitz J

更新日期：2008-11-01 00:00:00

abstract：:We report the case of a patient with schizophrenia who developed urinary hesitancy and eventually urinary retention, 6 months after continuous treatment with ziprasidone; he had been administered no other medication during this time. The micturition difficulties resolved immediately upon discontinuation of ziprasidone...

journal_title：International clinical psychopharmacology

authors： Xomalis D,Bozikas VP,Garyfallos G,Nikolaidis N,Giouzepas J,Fokas K

更新日期：2006-01-01 00:00:00